Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Neuropathy

    New York, NY

    Search
    Neuropathy
    New York, NY
    Show Map
    Map View
    New York, NY
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      80 Neuropathy Trials near New York, NY

      Power is an online platform that helps thousands of Neuropathy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      BION-1301 for IgA Nephropathy

      New York, New York
      This trial is testing BION-1301, a new medication, in adults with IgA nephropathy. The goal is to see if it can help reduce the amount of protein leaking into their urine by improving kidney function.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Type 1 Diabetes, Nephrotic Syndrome, HIV, Others
      Must Be Taking:ACEi, ARB, SGLT2i, ERAs

      383 Participants Needed

      LNP023 for IgA Nephropathy

      New York, New York
      The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Secondary IgAN, Hypertension, Infections, Others
      Must Be Taking:ACEi, ARB

      518 Participants Needed

      TARPEYO® for Immunoglobulin A Nephropathy

      New York, New York
      The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Other Glomerulopathies, Nephrotic Syndrome, Dialysis, Others
      Must Be Taking:TARPEYO, RAS Inhibitors

      60 Participants Needed

      Sibeprenlimab for IgA Nephropathy

      New York, New York
      This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Chronic Kidney Disease, Others
      Must Not Be Taking:Systemic Corticosteroids, Immunosuppression

      25 Participants Needed

      ADX-097 for Immunoglobulin A Nephropathy

      New York City, New York
      A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Significant Renal Disease, Uncontrolled Hypertension, Others
      Must Be Taking:RAAS Inhibitors, SGLT2 Inhibitors

      30 Participants Needed

      ALXN2050 for Kidney Disease

      New York, New York
      This trial tests a new medication, ALXN2050, in adults with serious kidney diseases (LN or IgAN). The goal is to improve kidney function and manage symptoms.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      126 Participants Needed

      Pegcetacoplan for Complement 3 Glomerulopathy

      New York, New York
      This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Drug Abuse, Others
      Must Be Taking:Pegcetacoplan

      100 Participants Needed

      Sparsentan for Proteinuria After Kidney Transplant

      New York, New York
      To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Multiorgan Transplants, Active Infection, Heart Failure, Malignancy, Others
      Must Be Taking:ACEI, ARB, SGLT2 Inhibitors

      20 Participants Needed

      Povetacicept for Autoimmune Kidney Diseases

      Brooklyn, New York
      The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Other Renal Disease, EGFR <30, Others
      Must Be Taking:ACEis/ARBs

      72 Participants Needed

      Sparsentan for Proteinuric Kidney Disease

      New York, New York
      This trial is testing sparsentan, a daily oral medication, in children with specific kidney diseases that cause high protein levels in urine. The goal is to see if it is safe and effective. Sparsentan helps by reducing protein leakage into the urine, which can protect the kidneys.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:1 - 17

      Key Eligibility Criteria

      Disqualifiers:Heart Failure, Liver Disease, Malignancy, Others
      Must Be Taking:ACEI, ARB

      67 Participants Needed

      Pegcetacoplan for Recurrent Kidney Disease

      New York, New York
      This trial is testing a medication called pegcetacoplan in patients who have had their kidney disease come back after a transplant. The medication aims to reduce inflammation and prevent further kidney damage by blocking certain immune system activities. The study will evaluate how safe and effective this treatment is for these patients.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others

      13 Participants Needed

      Lorundrostat + Dapagliflozin for Kidney Disease

      Brooklyn, New York
      This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      60 Participants Needed

      Iptacopan for Membranoproliferative Glomerulonephritis

      New York, New York
      This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:12 - 60

      Key Eligibility Criteria

      Disqualifiers:Transplantation, Chronic Infections, Autoimmune Diseases, Others
      Must Be Taking:RAS Inhibitors

      106 Participants Needed

      Felzartamab for Membranous Nephropathy

      The Bronx, New York
      In this study, researchers will learn more about the use of felzartamab in participants with primary membranous nephropathy, also known as PMN. In people with PMN, autoantibodies build up in the glomeruli of the kidney. Antibodies are proteins that help the body fight off infection. An autoantibody is a type of antibody that mistakenly targets and attacks the body's own tissues. Glomeruli are the filters of the kidney that remove waste and extra fluid from the body. In PMN, the build-up of autoantibodies in the glomeruli causes damage to the kidneys. Kidney damage can lead to too much protein and blood leaking into the urine. High levels of protein in the urine, called proteinuria, are common in people with PMN. Symptoms of PMN can include swelling in the legs and body, tiredness, and high blood pressure. If left untreated, PMN can eventually lead to kidney failure. In this study, researchers will learn more about how a study drug called felzartamab affects people with PMN. Felzartamab is a monoclonal antibody, which means it is an antibody made in a laboratory. Felzartamab can target immune cells that produce autoantibodies, helping to lower their buildup in the kidneys. The main goal of this study is to compare how felzartamab works compared to a drug called tacrolimus. Tacrolimus is another drug given to people with PMN and kidney disease. The main question that researchers want to answer is: * How many participants achieve a complete response after 104 weeks of treatment? * A complete response means that their urine protein levels decrease to a low level and their kidney function remains stable. Researchers will also learn about: * How long it takes before the participants' disease gets worse * How long the participants' urine protein levels stay low * How many participants develop antibodies against felzartamab in the blood? * How many participants achieve a complete response after 76 weeks of treatment * How many participants have medical problems during the study * How felzartamab is processed by the body * How felzartamab affects participants' tiredness and overall physical health The study will be done as follows: * Participants will be screened to check if they can join the study. This may take up to 42 days. * Participants will be randomized to receive either felzartamab as intravenous (IV) infusions or tacrolimus, taken orally as tablets. * If participants have worsening kidney function or worsening proteinuria, or if their PMN relapses, or if they show no signs of improvement in their PMN, they will have a chance to receive rescue treatment. * If a participant stops treatment early, there will be follow-up visits every 12 weeks until they reach Week 104. * In total, participants will have up to 23 study visits. Participants who do not need rescue treatment will stay in the study for up to 104 weeks. Participants who need rescue treatment will stay in the study for up to 156 weeks.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Secondary MN, Severe Renal Impairment, Others
      Must Be Taking:ACEI Or ARB

      180 Participants Needed

      Felzartamab for IgA Nephropathy

      The Bronx, New York
      In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much does the amount of protein in the urine change from the start of the study to Week 36? Researchers will learn about the effect felzartamab has on the kidneys' ability to filter blood. They will also learn more about the safety of felzartamab and how it is processed by the body. The study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will be randomized to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know what the participants will receive. * Participants will receive felzartamab or placebo as intravenous (IV) infusions. The treatment period will last 24 weeks. * Afterwards, participants will enter a follow-up period which will last 80 weeks. * In total, participants will have 17 study visits. Participants will stay in the study for about 2 years.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Secondary IgAN, Nephrotic Syndrome, Diabetes, Immunodeficient, Others
      Must Be Taking:ACEI, ARB, SGLT2is, ERAs

      454 Participants Needed

      Atacicept for IgA Nephropathy

      New York, New York
      This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Secondary IgAN, Nephrotic Syndrome, Uncontrolled Diabetes, Others
      Must Be Taking:RAASi

      376 Participants Needed

      Belimumab + Rituximab for Kidney Disease

      New York, New York
      The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy. Background: Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life. Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine. Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects. In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again. Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Secondary MN, Poor Diabetes Control, HIV, Others
      Must Be Taking:RAS Blockers

      58 Participants Needed

      Testosterone Nasal Gel for Spinal Cord Injury

      The Bronx, New York
      Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known about the relationships between T, nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI exhibit persistently low T concentrations, which may worsen nerve and ANS dysfunction. In uninjured eugonadal people (normal physiologic range of serum T concentrations), a single pharmacologic dose of intranasal T has been shown to quickly improve nerve function, but no study has evaluated if T administration alters nerve and ANS function in men with SCI. Herein, the investigators will conduct the first study to test how a single dose of intranasal T impacts motor and ANS function in this population.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Early Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Seizures, Ventilator Dependence, Others
      Must Not Be Taking:Amphetamines, Neuroleptics, Others

      15 Participants Needed

      Transspinal Stimulation for Spinal Cord Injury

      Staten Island, New York
      A well-established rehabilitation strategy for improvements of standing and walking ability in persons with spinal cord injury (SCI) is step training on a motorized treadmill with body weight support. A promising intervention is stimulation of the spinal cord through the skin (transspinal). No single intervention is likely to significantly improve long-term function after SCI on its own. Rather, combinatorial treatments that work synergistically and can be used at different clinical settings is the answer to target recovery in people with SCI. The objective of this clinical trial is to develop a non-invasive combinatorial intervention that can be used worldwide in different clinical settings. The investigators will use cervical and lumbosacral transspinal stimulation to augment the benefits of locomotor training and affect vital body functions after SCI. The investigators will deliver non-invasive cervical and lumbosacral transspinal stimulation alone or with step training to improve upright posture, walking, bladder, sex, and bowel function in persons with incomplete SCI. The noninvasive nature of the intervention holds minimal risk that outweighs the benefits.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Supraspinal Lesions, Neuropathies, Degenerative Disorders, Others

      36 Participants Needed

      RO7434656 for IgA Nephropathy

      Mineola, New York
      This trial is testing a new treatment that uses small genetic pieces to block harmful proteins in people with a specific kidney disease that isn't improving with current treatments. The treatment aims to stop the body from making proteins that make the disease worse.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Diabetes, Hypertension, Substance Abuse, Others
      Must Be Taking:Ace Inhibitors, Arbs

      428 Participants Needed

      Why Other Patients Applied

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Neuropathy Trial
      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Neuropathy clinical trials in New York, NY pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Neuropathy clinical trials in New York, NY work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Neuropathy trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY for Neuropathy is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Neuropathy medical study in New York, NY?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Neuropathy clinical trials in New York, NY?

      Most recently, we added Virtual Reality Self-Hypnosis for Pain Relief, Desloratadine for Nerve Damage in Breast Cancer and Sparsentan for Proteinuria After Kidney Transplant to the Power online platform.

      Does anything really work for neuropathy?

      Yes—real results come from tackling neuropathy on two fronts. First, fix the underlying cause whenever possible (tighten blood-sugar control, replace low B-12, adjust thyroid levels, stop a toxic medication, or use immune treatment for disorders like CIDP) because this can slow or even reverse nerve damage. Second, control the discomfort with proven options—prescription pills such as duloxetine or pregabalin/gabapentin, high-dose capsaicin or lidocaine skin patches, plus regular aerobic exercise and physical therapy—which can markedly cut burning, tingling or numbness while the root problem is being addressed.

      What triggers neuropathy flare-ups?

      A neuropathy “flare” usually happens when already-injured nerves face extra stress. The most common stressors fall into four buckets: 1) metabolic swings such as high or rapidly changing blood sugar or low vitamin B12, 2) lifestyle chemicals like alcohol or smoking, 3) mechanical or environmental insults—tight shoes, prolonged pressure, cold or heat, vibrations—or 4) medicines and illnesses that irritate nerves (certain chemotherapies, infections, thyroid or kidney problems). Tracking your symptoms alongside these factors (e.g., glucose readings, alcohol intake, recent medications, exposures) can help you and your doctor pinpoint personal triggers and plan ways to avoid them.

      Is foot neuropathy progressive?

      Most kinds of foot neuropathy do tend to worsen over time, especially when the underlying cause—such as poorly controlled diabetes, ongoing alcohol use, or certain chemotherapy drugs—continues to injure the nerves. Progression is not inevitable, though; correcting a vitamin-B12 shortage, improving blood-sugar levels, changing a medication, or simply protecting the feet can slow, stop, and sometimes partly reverse the damage. The takeaway: work with your clinician to pin down the cause early and tackle those risk factors so the condition doesn’t silently advance.

      Are eggs bad for neuropathy?

      For most people with neuropathy, an egg or two a few times a week is safe and can even help by providing vitamin B12 and choline that nerves need; the exception is if you have an egg allergy or your doctor has asked you to limit cholesterol. Focus on a balanced plate—plenty of vegetables, whole grains, and lean proteins—while monitoring blood sugar, weight, and how your body feels after different foods; if eggs don’t trigger symptoms and your lab numbers stay on target, they aren’t “bad” for your neuropathy.

      What is often mistaken for neuropathy?

      Several other problems can create numbness, tingling or burning, so neuropathy is often confused with a pinched nerve in the spine (radiculopathy), poor circulation to the legs and feet (peripheral artery disease), widespread pain disorders like fibromyalgia, vitamin B-12 deficiency, restless-leg syndrome, or brain/spinal-cord diseases such as multiple sclerosis. Notice whether symptoms stay in one limb, change with posture or walking, improve when you move, or come with fatigue, vision or wound-healing issues—those patterns can hint at a cause other than nerve damage. Because each condition has different treatments, any persistent or worsening sensation changes should be evaluated by a healthcare professional.

      Can nerves regenerate from neuropathy?

      Peripheral nerves can regrow, but they do so slowly—about a millimetre a day—so recovery takes months and is most successful when the underlying cause (like diabetes, vitamin B-12 deficiency, or pressure on a nerve) is corrected early. Full return of feeling or strength isn’t guaranteed, yet good blood-sugar control, stopping toxins (alcohol, certain drugs), proper vitamins, and guided exercise greatly improve the odds; nerves in the brain or spinal cord, however, rarely regenerate. In short, ask your doctor to hunt for—and treat—the cause, protect the numb area while healing occurs, and be patient with the gradual progress.

      What vitamin is used for neuropathy?

      The best-studied “nerve vitamins” are B-vitamins—especially B12 (about 1 mg daily or by injection for deficiency) and the B1 derivative benfotiamine (150–300 mg twice daily)—which small clinical trials show can improve nerve pain and conduction in diabetic or alcoholic neuropathy; vitamin B6 helps only if levels are low and should stay below 100 mg a day to avoid toxicity. Emerging research suggests that correcting low vitamin D (e.g., 1000–2000 IU daily, or higher short courses under medical supervision) may ease diabetic nerve pain, whereas other vitamins or minerals have little proof. Because dosing and causes of neuropathy vary, ask your doctor to measure B12 and vitamin D levels and guide any supplementation.

      Is there a walking device for neuropathy?

      Yes. Options range from sensory-substitution wearables like Walkasins that vibrate above the ankle to restore lost foot feedback, to functional-electrical-stimulation braces for foot-drop and standard aids such as canes or trekking poles; each targets different neuropathy-related walking problems. A physical therapist or neurologist can test your sensation and balance and let you trial the device type most likely to improve your safety and confidence.

      How to stop neuropathy from progressing?

      Nerves keep getting damaged only if the thing that is hurting them stays active, so the first step is to have a doctor pin down the exact cause—-for example high blood sugar, low vitamin B-12, alcohol, a pinched nerve, or an immune condition—and treat or remove it right away. At the same time, you can give the nerves their best chance to stabilise by exercising gently every day, eating a nutrient-rich diet, stopping smoking and excess alcohol, and checking your feet and skin daily for injuries you might not feel.

      Do magnets help neuropathy?

      Current research on magnets for neuropathy is sparse and low-quality; small studies sometimes show pain relief, but just as many find no difference, and no professional guidelines endorse magnetic devices for neuropathic pain. Magnets appear harmless for most people (keep them away from pacemakers), but because evidence of benefit is weak, they should be viewed—at best—as an optional add-on rather than a substitute for proven treatments like good glucose control, exercise, medications (e.g., duloxetine, gabapentin), and foot care.

      Popular Searches

      By Condition

      Depression Clinical Trials in New York

      Anxiety Clinical Trials in New York

      Schizophrenia Clinical Trials in New York

      ADHD Clinical Trials in New York

      Bipolar Disorder Clinical Trials in New York

      Multiple Sclerosis Clinical Trials in New York

      Autism Clinical Trials in New York

      Treatment Resistant Depression Clinical Trials in New York

      Borderline Personality Disorder Clinical Trials in New York

      Social Anxiety Disorder Clinical Trials in New York

      Parkinson's Disease Clinical Trials in New York

      Alzheimer's Disease Clinical Trials in New York

      By Location

      Clinical Trials near New York, NY

      Clinical Trials near Rochester, NY

      Clinical Trials near Bronx, NY

      Clinical Trials near The Bronx, NY

      Clinical Trials near Buffalo, NY

      Clinical Trials near Brooklyn, NY

      Clinical Trials near Syracuse, NY

      Clinical Trials near Albany, NY

      Clinical Trials near Stony Brook, NY

      Clinical Trials near Manhasset, NY

      Clinical Trials near New Hyde Park, NY

      Clinical Trials near Mineola, NY

      Other People Viewed

      By Subject

      Top Clinical Trials near Kansas

      Top Ctcl Clinical Trials

      26 Alzheimer's Disease Trials near Vancouver, WA

      Top Social Anxiety Disorder Clinical Trials

      Top Diabetes Clinical Trials near Chicago, IL

      Top Clinical Trials near Madison, WI

      155 Clinical Trials near Beaver Falls, PA

      77 Clinical Trials near Las Vegas, NV

      Top Clinical Trials near Attleboro, MA

      Top Breast Cancer Clinical Trials near Chicago, IL

      Top Clinical Trials

      Top Transcranial Magnetic Stimulation Clinical Trials

      By Trial

      Iptacopan for Myasthenia Gravis

      M2VA Pain Care Pathway for Pain

      Inhaled Nitric Oxide for Stroke

      VT Ablation Before LVAD Surgery for Arrhythmia

      Exercise for Pediatric Cancer

      Exercise for Ovarian and Endometrial Cancer Patients

      PF-07220060 + Letrozole for Breast Cancer

      11C-BMS-986196 for Multiple Sclerosis

      RAPA-201 Immunotherapy for Solid Cancers

      MOMS Intervention for Prenatal Stress

      Social Network Coaching for Cancer

      Intrathecal Morphine for Labor Pain